ClinicalTrials.gg
Not yet recruitingNCT05611190Updated Nov 9, 2022

CT-FFR-guided Strategy for In-stent Restenosis

An interventional study of CT-FFR and Usual Care in Coronary Artery Disease and In-stent Restenosis, sponsored by Yan'an Affiliated Hospital of Kunming Medical University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-09.

Sponsored by Yan'an Affiliated Hospital of Kunming Medical University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
294
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will be a prospective, randomized clinical trial to compare standard practice guided by usual care testing to CT-FFR-guided management in patients with in-stent restenosis.

Read the detailed description

This trial will randomize 294 patients with in-stent restenosis to receive either CT-FFR or routine clinical assessment. In all subjects, the investigators will review all diagnostic test results and determine a treatment strategy. The primary end point will be 12-month Major Adverse Coronary Event (MACE) rates, defined as all cause death, non-fatal myocardial infarction (MI), ischemia-driven target vessel revascularization (TVR). Secondary end points will include total medical costs, and quality of life (QOL), medical radiation exposure, etc. We will test noninferiority of current FFR-guided strategy compared with standard care strategy.

02

Conditions studied

  • Coronary Artery Disease
  • In-stent Restenosis

Keywords

  • Coronary CT Angiography-derived Fractional Flow Reserve
  • In-stent Restenosis
  • Major Adverse Coronary Events
03

In context

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

This study's planned enrollment of 294 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Yan'an Affiliated Hospital of Kunming Medical University is the lead sponsor of 9 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) >18 years old;
  • (2) ability to provide ;
  • (3) previous PCI who underwent CCTA and have at least 1 lesion with a percent diameter in-stent stenosis between 30% and 90% in a coronary artery with a ≥2.25 mm reference vessel diameter by visual assessment;
  • (4) accepted further clinically indicated coronary testing, coronary arteriography, or FFR, or IVUS, or PCI, etc.

Exclusion criteria

Exclusion Criteria:

  • (1) Prior coronary artery bypass surgery (CABG), heart valve surgery, cardiac pacemaker, or implanted cardiac defibrillator;
  • (2) Target vascular stents were evaluated for implantation within one month;
  • (3) unstable clinical conditions including acute chest pain, cardiogenic shock, congestive heart failure ( grade III or IV), unstable blood pressure (systolic blood pressure \< 90mmHg) or acute pulmonary edema;
  • (4) Acute myocardial infarction occurred within 7 days before enrollment, and ≤40%;
  • (5) Other severe cases are not suitable for clinical trials including complex congenital heart disease, sick sinus syndrome, long syndrome, severe arrhythmia, tachycardia, severe asthma, severe or very severe (COPD) and severe chronic renal damage;
  • (6) to beta blockers, nitroglycerin, adenosine, or allergy to iodine contrast agents;
  • (7) Pregnancy or pregnancy status unknown;
  • (8) \<1 years;
  • (9)Repeated enrollment;
  • (10) Any other factors that other researchers consider not suitable for inclusion or completion of this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
294 participants (estimated)

Study arms

  • Other
    Usual Care

    Participants randomized to usual care will be evaluated according to institutional standard practice. The investigators will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice.

    Diagnostic Test: Usual Care

  • Experimental
    CT-FFR

    Participants randomized to a CT-FFR strategy will be assigned to non-invasive CT-FFR evaluation. The investigators will review the results CT-FFR, and will recommend a further ICA test if CT-FFR≤0.8. The investigators will review the results of all available diagnostic tests, including CT-FFR and ICA, and will recommend a treatment strategy accordingly.

    Diagnostic Test: CT-FFR

Interventions

  • Diagnostic testCT-FFR

    CT-FFR is a type of non-invasive procedure to provide a 3D model of coronary arteries as a way to evaluate the hemodynamic significance of coronary artery lesions. CT-FFR calculates FFR from subject-specific CCTA data using computational fluid dynamics technology. CT-FFR value ≤0.80 is considered hemodynamically significant.

  • Diagnostic testUsual Care

    Participants randomized to usual care will be evaluated according to institutional standard practice.

06

What researchers measure

Primary outcomes

  1. 12-month MACE

    12-month Major Adverse Coronary Event (MACE) rates, defined as: 1. All cause death 2. Non-fatal myocardial infarction (MI) 3. Ischemia-driven target vessel revascularization (TVR)

    Time frame: 12 months

Secondary outcomes

  1. MACE

    MACE defined as: 1. All cause death 2. Non-fatal MI 3. Clinical-driven TVR

    Time frame: 3-month, 6-month, 24-month, 36-month

  2. Rates of Target lesion failure (TLF)

    Composite of clinically driven TLR, MI or cardiac death related to the target vessel.

    Time frame: 3-month, 6-month, 24-month, 36-month

  3. Total costs

    Total costs will be calculated from the use of all cardiac-related invasive and non-invasive tests, revascularization procedures, hospital admissions and outpatient attendances due to a cardiovascular cause, and cardiac medications.

    Time frame: 6-month, 12-month

  4. Quality of life (QOL) will be assessed using the EQ-5D-VAS questionnaire

    Quality of life (QOL), will be assessed using the EQ-5D-VAS questionnaire

    Time frame: 6-month, 12-month

  5. Seattle Angina Questionnaire

    angina status, will be assessed using the Seattle Angina Questionnaire

    Time frame: 6-month, 12-month

  6. Cumulative radiation exposure

    Cumulative radiation exposure within 6-month and 12-month of study entry included all cardiovascular tests and invasive procedures, including CTA, myocardial perfusion imaging, and ICA.

    Time frame: 6-month, 12-month

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2022; primary completion for Dec 2024, 23 months later.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 23 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2022
First posted
Nov 9, 2022
StartEst.
Dec 12, 2022
Primary completionEst.
Dec 11, 2024
CompletionEst.
Dec 11, 2025
Last update
Nov 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05611190
Lead sponsor
Yan'an Affiliated Hospital of Kunming Medical University
Responsible party
Sponsor
First posted
Nov 9, 2022
Start date
Dec 12, 2022 (estimated)
Primary completion
Dec 11, 2024 (estimated)
Completion
Dec 11, 2025 (estimated)
Last update
Nov 9, 2022

Study contacts

Qiang Xue
Contact
Xueqiang3513@126.com
13987199913
Qiang Xue
principal investigator · Yan'an Affiliated Hospital of Kunming Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion